key: cord-0833094-8hlbj799
authors: Nasiri, Naser; Rahmati, Shoboo; Etminan, Abbas; Sharifi, Hamid; Bazrafshan, Azam; Karamouzian, Mohammad; Sharifi, Ali
title: Kidney Complications of COVID-19: A Systematic Review and Meta-Analysis
date: 2021-01-12
journal: J Res Health Sci
DOI: 10.34172/jrhs.2021.39
sha: e7486d0bbd94fcdc198f08fd394e5f2f5e67c8c0
doc_id: 833094
cord_uid: 8hlbj799

Background: Some patients with coronavirus disease 2019 (COVID-19) have been reported to have developed mild to severe kidney injuries. The current systematic review and meta-analysis was carried out to estimate the prevalence and incidence of acute kidney injury (AKI) among COVID-19 patients. Study design: A systematic review and meta-analysis Methods: PubMed, Embase, Scopus, Web of Science, and MedRxiv databases were searched from December 1, 2019, up to July 27, 2020. Two independent co-authors completed the screening process, data extraction, and quality assessment of the retrieved records. Random-effects meta-analyses were used to determine the pooled prevalence and 95% confidence interval (CI) of AKI among COVID-19 patients. Results: Out of 2,332 unique identified records, 51 studies were included in the review. Overall, the studies were carried out on 25,600 patients. A total of 6,505 patients (in 18 cross-sectional studies) were included to estimate the pooled prevalence of AKI, and 18,934 patients (in 27 cohort studies) were included to determine the pooled incidence of AKI. The pooled prevalence of AKI was estimated as 10.08% (95% CI: 4.59, 17.32; I (2)=98.56%; P<0.001). Furthermore, the pooled incidence of AKI was 12.78% (95% CI: 7.38, 19.36; I (2)=99.27%; P<0.001). The mean (95% CI) values of serum creatinine (SCr), blood urea nitrogen (BUN), potassium, and sodium were 76.10 (69.36, 82.84), 4.60 (4.04, 5.30), 3.94 (3.78, 4.11), and 139.30 (138.26, 140.36) mmol/L, respectively. Conclusions: The AKI is a considerable complication among COVID-19 patients and should be screened for on clinical examinations. The BUN, SCr, potassium, and sodium levels were within the normal ranges.

evere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly spread around the globe 1 , and coronavirus disease 2019 (COVID-19) was declared a pandemic by the World Health Organization in March 2020 2 . By October 11, 2020, more than 37 million individuals had been infected with COVID-19, and 1,078,715 cases had died due to COVID-19 3 . The SARS-CoV-2 enters the host cells and binds to angiotensin-converting enzyme 2 (ACE2) receptors 1 . Most COVID-19 patients have multiple signs or symptoms; however, commonly reported signs and symptoms are fever, fatigue, dry cough, and muscular pain 4 . COVID-19 is more common among individuals with multimorbidities, such as hypertension, diabetes, cardiovascular, and respiratory diseases 5 .

Different internal organs, such as heart, liver, and kidney, can be damaged in COVID-19 patients 6 . The results of studies showed that ACE2 is the central receptor to enter pathogens in human cells 7, 8 . The ACE2 is expressed in kidneys 9 and exists in proximal tubule cells 8 . The SARS-CoV-2 can particularly affect kidneys and lead to acute kidney injury (AKI) 9 . Several studies have reported AKI and increased blood urea nitrogen (BUN) and serum creatinine (SCr) in COVID-19 patients 6, 10, 11 . For example, Yang et al. reported that 13.7% and 9.6% of COVID-19 patients had elevated BUN and SCr levels, respectively 10 . Moreover, AKI has also been shown to increase the probability of mortality among COVID-19 patients, and different studies have reported varying prevalence of AKI 5, 11, 12 . The present systematic review aimed

Studies reporting on the kidney complications of COVID-19 with any design, including case reports, case series, cohorts, and cross-sectional studies, were eligible for this systematic review. However, only cross-sectional and cohort studies were considered for meta-analysis. Non-original studies, such as editorials, letters to the editor, commentaries, and reviews, were excluded from the study. Studies obtained through the electronic database searching were transferred to EndNote software version X8. Two independent co-authors (SHR and AB) completed the title, abstract, and full-text screening process. Any disagreement on the process of selected studies was resolved by discussion with the senior co-author and a nephrologist co-author (ASH and AE).

Data were independently extracted from the eligible studies by two co-authors (NN and SHR). The items considered in data extraction included study characteristics (e.g., first author, publication date, study design, study location, and sample size) and participant characteristics (e.g., age, sex, kidney complications, and laboratory test results).

The Joanna Briggs Institute critical appraisal tool was used to assess the quality of the included studies 14 . This tool evaluates quality with differential items, including 8 items for case report studies, 10 items for case series, 9 items for crosssectional studies, and 11 items for cohort studies.

Descriptive statistics (i.e., mean, median, and standard deviation [SD] for continuous variables and frequency and percentage for categorical variables) were used in this study. Weighted means were utilized to estimate the pooled mean and 95% confidence interval (CI) of laboratory tests. The Metaprop command in Stata software was used to determine the pooled prevalence and incidence of AKI and associated 95% CI of kidney complications. Random-effects metaanalysis was used in the study. The heterogeneity among the included studies was assessed using I 2 and Q-statistic. A value of ≥ 50% of I 2 and p-value of < 0.1 for the Q-statistic were regarded as considerable heterogeneity. Then, a metaregression was fitted to assess the potential sources of heterogeneity. For fitting the meta-regression, several variables, namely diagnostic method of COVID-19 (i.e., polymerase chain reaction [PCR] vs. computed tomography [CT] scan and clinical signs), quality of studies (i.e., a quality score of ≥ 4 vs. quality score of < 4), number of study centers (i.e., multi-center vs. single-center), and recruited sample size (i.e., a sample size of > 500 vs. sample size of ≤ 500), were included. Stata software (version 14.2) was used for all statistical analyses. In addition, all comparisons were twotailed with a threshold p-value of ≤ 0.05 for statistical significance.

Out of the 2,332 retrieved unique records, 51 studies were included in the present systematic review 4, 5, (Figure 1 ). Four studies were case reports [60] [61] [62] [63] , and two studies were case series 28,29 . Furthermore, 27 studies were cohort 4, 5, 16, 17, 19, 21, 24, 27, 31, [33] [34] [35] [37] [38] [39] 46, 47, [49] [50] [51] [52] [53] [54] [55] [56] 58, 59 , and 18 studies were cross-sectional 15 Table 1 tabulates the demographic and clinical characteristics of the patients included in the studies. 

The overall quality of the studies was low. The scores of the case report, case series, cross-sectional, and cohort studies were within the ranges of 2-5 (out of 8 possible points), 2-3 (out of 10 possible points), 1-6 (out of 9 possible points), and 3-7 (out of 11 possible points), respectively. Supplementary file S4 shows further details in this regard.

The pooled prevalence of AKI was estimated based on the data obtained from 18 cross-sectional studies carried out on 6,505 patients ( Figure 2 ). The pooled prevalence of AKI was estimated as 10.08% (I 2 =98.56; 95% CI: 4.59, 17.32; P<0.0001).

The pooled incidence of AKI was estimated based on the data obtained from 27 cohort studies conducted on 18,934 patients ( Figure 3 ). The pooled incidence of AKI was estimated as 12.78% (I 2 =99.27; 95% CI: 7.38, 19.36; P<0.0001).

The mean (95% CI) values of SCr, BUN, potassium, and sodium among patients diagnosed with COVID-19 were estimated as 76. 10 

The results of meta-regression did not reveal the significant sources of heterogeneity among the studies included in the present meta-analysis (Table 3 ).

This systematic review and meta-analysis included 51 studies and 25,600 COVID-19 patients. Based on the included evidence, it was estimated that the prevalence and incidence of AKI were about 10% and 12%, respectively. These findings are comparable with previous results varying greatly across different studies. For example, in a study carried out by Pei et al. in China, the incidence of AKI was reported as 4.7% (22 out of 467) 54 metabolism. In addition, damages to kidneys and accumulation of drugs could increase toxin accumulation in patients 68, 69 . Kidney injuries increase the severity of the disease among COVID-19 patients and need for mechanical ventilation 11, 37 . In a recent meta-analysis, the pooled odds ratio for mortality among COVID-19 patients with AKI was reported as 13.3 11 . Paying further attention to kidney injuries in the clinical assessment of patients could help decrease COVID-19-related morbidities and mortalities. 42 . However, the weighted mean values of BUN and SCr were within the normal ranges in the included studies. This could be due to the fact that the included studies calculated the weighted mean of BUN and SCr for all COVID-19 patients and not separately for those with AKI. Therefore, the assessment of BUN and SCr in COVID-19 patients with AKI would be informative.

The weighted mean values of potassium and sodium were 3.94 (range: 3.7-4.2) and 139.3 (range: 137-141.2) mmol/L, respectively. The normal ranges of potassium and sodium are 3.5-5.3 and 137-147 mmol/L, respectively. The assessment of the baseline levels of electrolytes can help evaluate the risk of mortality among COVID-19 patients 71 . Sodium may also help predict progression to severe disease in COVID-19 patients 72 . Sodium and potassium levels could be lower in severe COVID-19 cases 73 . For example, Tezcan et al. reported that low baseline sodium was related to higher mortality in COVID-19 patients 71 . In addition, hypernatremia can be a manifestation of COVID-19 and adverse outcomes in COVID-19 cases 74 .

Although sodium and potassium levels are important in COVID-19 patients, the current study showed sodium and potassium levels to be within the normal ranges. This could be due to the fact that the studies measured sodium and potassium only once during the course of the study. Therefore, it is suggested to carry out further studies to measure sodium and potassium levels in the initial admission of patients and continue monitoring the patients' sodium and potassium levels throughout their hospital admission.

The current study had several limitations. Firstly, the quality of studies included in the meta-analysis was low. Secondly, most studies had a low sample size. Thirdly, the variations between studies could lead to different measurements. Fourthly, the diagnostic methods were the use of PCR in some studies and clinical signs and CT scans in other studies that can be taken into account when interpreting the findings. Nonetheless, the findings of the present study are informative for the enhancement of the identification of AKI among COVID-19 patients.

The prevalence and incidence of AKI seem to be considerable among COVID-19 patients. The BUN, SCr, sodium, and potassium were within the normal ranges. The assessment and monitoring of COVID-19 patients for renal complications and comorbidities can help improve care and health outcomes among COVID-19 patients. and AB. ASH and AE supervised the screening process. Data extraction was carried out by NN and SHR. Data analysis was performed by HSH and MK. NN, HSH, MK, and ASH wrote the first draft of the manuscript. The manuscript was read and approved by all the authors.

 Acute kidney injury is a prevalent complication among coronavirus disease 2019 (COVID-19) patients.

 Monitoring COVID-19 patients for renal injuries could help improve their health outcomes.

 Overall, blood urea nitrogen, serum creatinine, sodium, and potassium were within the normal ranges among the included patients in the review.

COVID-19-New Insights on a Rapidly Changing Epidemic

Epidemiological characteristics of COVID-19: a systematic review and meta-analysis

Worldmeter-real time world statistics

Clinical Features and Short-term Outcomes of 102 Patients with Coronavirus Disease

Clinical characteristics of coronavirus disease 2019 in China

Association of particulate matter pollution and case fatality rate of COVID-19 in 49 Chinese cities

ACE2 expression in kidney and testis may cause kidney and testis damage after 2019-nCoV infection

Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis

Single-cell RNAseq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection

Prevalence and impact of acute renal impairment on COVID-19: a systematic review and meta-analysis

Incidence of acute kidney injury and its association with mortality in patients with COVID-19: a meta-analysis

Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The Joanna Briggs Institute Critical Appraisal tools for use in JBI systematic reviews

Comparison of clinical characteristics and outcomes of patients with coronavirus disease 2019 at different ages

Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings

Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan

Patients with COVID-19 in 19 ICUs in Wuhan, China: a cross-sectional study

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Acute kidney injury in hospitalized patients with COVID-19

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series

Clinical characteristics of acute respiratory syndrome with SARS-CoV-2 infection in children in South China

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China

Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up

A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Clinical characteristics of SARS-CoV-2 infections involving 325 hospitalized patients outside Wuhan

Renal Involvement and Early Prognosis in Patients with COVID-19

Fatal Outcomes of COVID-19 in Patients with Severe Acute Kidney Injury

Clinical features and treatment of COVID-19 patients in northeast Chongqing

Prognostic factors in Spanish COVID-19 patients: A case series from Barcelona

Caution on kidney dysfunctions of COVID-19 patients

Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study

Venous thrombosis and arteriosclerosis obliterans of lower extremities in a very severe patient with 2019 novel coronavirus disease: a case report

Case 17-2020: A 68-Year-Old Man with Covid-19 and Acute Kidney Injury

A Continuous Renal Replacement Therapy Protocol for Patients with Acute Kidney Injury in Intensive Care Unit with COVID-19

Acute kidney injury in hospitalized patients with coronavirus disease 2019 (COVID-19): A meta-analysis

Outcomes for Patients With COVID-19 and Acute Kidney Injury: A Systematic Review and Meta-Analysis

Renal Complications and Their Prognosis in Korean Patients with Middle East Respiratory Syndrome-Coronavirus from the Central MERS-CoV Designated Hospital

Acute renal impairment in coronavirus-associated severe acute respiratory syndrome

Acute kidney injury in coronavirus disease 2019 infected patients: a metaanalytic study

Risk factors for acute renal failure: inherent and modifiable risks

Early prediction of acquiring acute kidney injury for older inpatients using most effective laboratory test results

Baseline electrolyte abnormalities would be related to poor prognosis in hospitalized coronavirus disease 2019 patients

Correlation between the variables collected at admission and progression to severe cases during hospitalization among patients with COVID-19 in Chongqing

Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19)

Hypernatremia-A manifestation of COVID-19: a case series

MK is a member of the COVID-19 Impact Committee of Pierre Elliott Trudeau Foundation and is supported by the Pierre Elliott Trudeau Foundation Doctoral Scholarship.

The authors declare that there is no conflict of interest.

This review received no external funding or other supports.

All the authors contributed to conceptualization, study design, and data analysis. Screening was completed by SHR